TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01717326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
Study: NCT06301932

Intervention type: PROCEDURE
Intervention: Open liver resection
Description: The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology

Intervention type: PROCEDURE
Intervention: Open liver resection
Description: The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
Study: NCT00232856

Intervention type: DEVICE
Group type: OTHER
Intervention: drug-eluting stent
Description: PCI
Study: NCT04831177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in situ keratomileusis
Description: Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in situ keratomileusis
Description: Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
Study: NCT01401608

Intervention type: DEVICE
Intervention: RF Ablation
Description: Ablation of arrhythmogenic ventricular tissue
Study: NCT01620944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Capsule, oral, 300 mg, Once daily (QD), 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsule, oral, 300 mg, Once daily (QD), 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Tablets, oral, 100 mg, QD, 96 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Tablets, oral, 100 mg, QD, 96 Weeks
Study: NCT03322644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT intervention
Description: The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
Study: NCT03376334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Motor Imagery
Study: NCT03783325

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: UV Counseling
Description: This is a sub-study that involves a behavioral intervention. Participants will wear a UV dosimetry for 3 weeks, return the device and receive feedback. After the feedback, they will re-wear the device for an additional 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV Photo
Description: Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological Sample
Description: Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
Study: NCT01739049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: liraglutide
Study: NCT01191359

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: oral immunotherapy
Description: orally applied specific immunotherapy
Study: NCT01739049

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: diet and exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: diet and exercise
Study: NCT06753461

Intervention type: PROCEDURE
Intervention: intrahepatic blood flow occlusion
Description: The specified blood vessel is temporarily clamped to achieve the intended blockage of blood flow.

Intervention type: PROCEDURE
Intervention: intrahepatic blood flow occlusion
Description: The specified blood vessel is temporarily clamped to achieve the intended blockage of blood flow.
Study: NCT01620944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Tablet, oral, 300 mg, QD, 96 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tablets, oral, 300/200 mg, QD, 48 Weeks
Study: NCT03852095

Intervention type: OTHER
Intervention: minor trauma
Description: following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
Study: NCT06753461

Intervention type: PROCEDURE
Intervention: intrahepatic blood flow occlusion
Description: The specified blood vessel is temporarily clamped to achieve the intended blockage of blood flow.
Study: NCT04445428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oral polio vaccine + information
Description: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
Study: NCT06758167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XingpiJieyu formula
Description: XingpiJieyu formula is a traditional Chinese medicine. It pays attention to the regulation of qi and blood. Previous studies have shown that its clinical effect of treating mild and moderate depression is significant, for example, it can effectively improve depressive mood and somatic symptoms, and increase peripheral blood ATP levels in patients with depression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, no therapeutic effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: A commonly used drug in MDD treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: A commonly used drug in MDD treatment.
Study: NCT04560998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
Study: NCT00980460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study: NCT03001453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 266mg liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine with epinephrine
Description: 0.25% bupivacaine with epinephrine
Study: NCT04445428

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information
Description: Advice regarding how to protect oneself from COVID-19

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Advice regarding how to protect oneself from COVID-19
Study: NCT04751149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Urinary Catheter
Description: Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Urinary Catheter
Description: Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Urinary Catheter
Description: Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
Study: NCT00032643

Intervention type: DRUG
Group type: OTHER
Intervention: DITPA
Study: NCT01561352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
Study: NCT02220244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003 100mg capsule
Study: NCT03001453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine with epinephrine
Description: 0.25% bupivacaine with epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline
Study: NCT00390208

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab, dexamethasone and verteporfin
Description: One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
Study: NCT04611451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classic lumbar home exercise
Description: classic lumbar home exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classic lumbar home exercise
Description: classic lumbar home exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Description: Whole body vibration exercise
Study: NCT03937492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMI protocol
Description: This group follow GMI program split in 3 step:~1. left/right descrimination~2. visual motor imagery~3. mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation Protocol
Description: This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation Protocol
Description: This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week.
Study: NCT04119011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: (Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
Study: NCT00980460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study: NCT00390208

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: One 0.5 mg intravitreal Ranibizumab injection
Study: NCT02862730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Dual Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subject's insulin pump
Description: Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Single Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
Study: NCT03959969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
Study: NCT05467787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based psychotherapy (MBP)
Description: Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-chat Psychotherapy (VCP)
Description: Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
Study: NCT01822106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02892149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Study: NCT04077944

Intervention type: DIAGNOSTIC_TEST
Intervention: maternal serum concentration of trace elements and heavy metals levels
Description: The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)

Intervention type: DIAGNOSTIC_TEST
Intervention: maternal serum concentration of trace elements and heavy metals levels
Description: The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
Study: NCT04134195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: 2mA stimulation for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: 2mA stimulation for 20 minutes
Study: NCT04587726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girl's room video
Description: Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~1. Appearance comparison~2. Body appreciation~3. Body talk~4. Body functionality~5. Appearance teasing \& bullying~6. Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020.
Study: NCT02013167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab is administered as a continuous intravenous infusion (CIV).
Study: NCT02111499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP3
Description: daily topical application
Study: NCT04587726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control video - Chicken Girls
Description: Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
Study: NCT00445146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG
Description: Elvitegravir (EVG) tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).